Back to mobile site

Oppenheimer Reiterates Outperform Rating on Kyntra Bio (KYNB)

September 1, 2026 3:56 AM EDT Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $35.00 price target on Kyntra Bio (NASDAQ: KYNB).The analyst comments "We're ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login